Latest Peripheral T-cell lymphoma-Not-Otherwise-Specified Stories
(Ivanhoe Newswire) - NK/T-cell lymphoma is a very aggressive form of cancer, and currently has no effective treatment along with having a poor prognosis. This subtype of lymphoma is pretty rare in the United States, but is responsible for a large number of deaths in Asia, particularly China and Korea. A substantial proportion of NK/T-cell lymphomas harbor Janus Kinase 3 gene mutations. Patients with these lymphomas might benefit from treatment with a Janus Kinase inhibitor according to a...
The product, once available in the clinic, could be the first to hit a pathway that drives multiple types of lymphoma, according to new research from Fox Chase. Scientists at Fox Chase Cancer Center in Philadelphia have come one step closer to developing the first treatment to target a key pathway in lymphoma. The new findings will be announced at the AACR Annual Meeting 2012 on Tuesday, April 3. "It's an exciting time to be involved in lymphoma treatment and research," says study...
PHILADELPHIA, Sept. 14 /PRNewswire/ -- TenX Biopharma, Inc. announced today that data from a Phase II trial of zanolimumab (HuMax-CD4®) in peripheral T-cell Lymphoma (PTCL) were published in the British Journal of Haematology (Sep 2010: 150(5):565-73). The Hx-CD4-109 trial was designed to evaluate the safety and efficacy of zanolimumab in patients who have relapsed or refractory non-cutaneous peripheral T-cell lymphoma. Twenty-one adult patients with relapsed or refractory CD4+ PTCL of...
NCCN has added pralatrexate (Folotyn(TM), Allos Therapeutics, Inc.) to the NCCN Guidelines for Non-Hodgkin's Lymphomas as one of the options for second-line therapy for relapsed or refractory peripheral T-cell lymphoma. The FDA-approved pralatrexate for the treatment of peripheral T-cell lymphoma on September 25, 2009 FORT WASHINGTON, Pa., Oct. 15 /PRNewswire-USNewswire/ -- Upon the recent FDA approval of pralatrexate (Folotyn(TM), Allos Therapeutics, Inc.) for the treatment of relapsed or...
The U.S. Food and Drug Administration has approved Folotyn as the first treatment for a form of cancer known as peripheral T-cell lymphoma. Folotyn (pralatrexate) was approved under the FDA's accelerated approval process, which allows earlier approval of drugs that meet unmet medical needs, officials said. It is approved for patients who have relapsed, or have not responded well to other forms of chemotherapy. Lymphoma is a cancer of the lymphatic system, which is part of the immune system,...
SILVER SPRING, Md., Sept. 25 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration has approved Folotyn (pralatrexate), the first treatment for a form of cancer known as Peripheral T-cell Lymphoma (PTCL), an often aggressive type of non-Hodgkin's lymphoma. (Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO) Folotyn was approved under the FDA's accelerated approval process, which allows earlier approval of drugs that meet unmet medical needs. It is approved for patients...
Preclinical Rationale for Clinical Trial Presented at USCAP Meeting SOUTH SAN FRANCISCO, Calif., March 13 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the enrollment of the first patient in a Phase 2, multi-center clinical trial of R788 (fostamatinib disodium) in patients with refractory or relapsed peripheral T-cell lymphoma (PTCL). The clinical trial's primary objective is to assess the efficacy of R788, an orally bio-available Syk kinase...
Allos Therapeutics, Inc. (NASDAQ: ALTH) today reported results for the third quarter of 2008. For the three months ended September 30, 2008, the Company reported a net loss of $13.2 million, or ($0.16) per share. This compares to a net loss of $9.3 million, or ($0.14) per share, for the third quarter of 2007. For the nine months ended September 30, 2008, the Company reported a net loss of $37.0 million, or ($0.50) per share, compared to a net loss of $28.1 million, or ($0.43) per share, for...
COPENHAGEN, Denmark, September 5 /PRNewswire-FirstCall/ -- TopoTarget A/S (OMX: TOPO) announced that a positive reply from the FDA was received on a Special Protocol Assessment (SPA) for a phase III trial for belinostat in PTCL (Peripheral T-Celle Lymphoma). This pivotal trial is to enrol approximately 120 patients and is to begin in Q4 2008. In June Fast Track designation was granted for the development of belinostat in this indication which supports TopoTarget's rapid market entry...
